These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32861505)

  • 1. The prevalence and clinical features of spasmodic dysphonia: A review of epidemiological surveys conducted in Japan.
    Hyodo M; Hisa Y; Nishizawa N; Omori K; Shiromoto O; Yumoto E; Sanuki T; Nagao A; Hirose K; Kobayashi T; Asano K; Sakaguchi M
    Auris Nasus Larynx; 2021 Apr; 48(2):179-184. PubMed ID: 32861505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum Toxin Therapy: A Series of Clinical Studies on Patients with Spasmodic Dysphonia in Japan.
    Hyodo M; Asano K; Nagao A; Hirose K; Nakahira M; Yanagida S; Nishizawa N
    Toxins (Basel); 2021 Nov; 13(12):. PubMed ID: 34941678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update.
    Hyodo M; Hirose K; Nagao A; Nakahira M; Kobayashi T
    Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education.
    Creighton FX; Hapner E; Klein A; Rosen A; Jinnah HA; Johns MM
    J Voice; 2015 Sep; 29(5):592-4. PubMed ID: 25873547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral Vocal Fold Medialization: A Treatment for Abductor Spasmodic Dysphonia.
    Dewan K; Berke GS
    J Voice; 2019 Jan; 33(1):45-48. PubMed ID: 29132808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulcus vocalis in spasmodic dysphonia-A retrospective study.
    Nerurkar NK; Agrawal D; Joshi D
    Am J Otolaryngol; 2021; 42(3):102940. PubMed ID: 33545449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience.
    Tisch SH; Brake HM; Law M; Cole IE; Darveniza P
    J Clin Neurosci; 2003 Jul; 10(4):434-8. PubMed ID: 12852881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Evaluation of Type 2 Thyroplasty with Titanium Bridges for Adductor Spasmodic Dysphonia.
    Sanuki T; Yumoto E
    Otolaryngol Head Neck Surg; 2017 Jul; 157(1):80-84. PubMed ID: 28463639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of phonosurgical methods of treatment in spasmodic dysphonia].
    Kosztyła-Hojna B; Berger G; Zdrojkowski M
    Pol Merkur Lekarski; 2017 Feb; 42(248):90-92. PubMed ID: 28258685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demographics and coexisting tremor, cervical dystonia and vocal fold disorders in a group of patients with spasmodic dysphonia.
    Karatayli Ozgursoy S; Vargas ER; Heckman MG; Rutt AL
    Acta Otorhinolaryngol Ital; 2020 Jun; 40(3):198-203. PubMed ID: 32773781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and demographics in patients with spasmodic dysphonia.
    Schweinfurth JM; Billante M; Courey MS
    Laryngoscope; 2002 Feb; 112(2):220-3. PubMed ID: 11889373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
    Meyer TK; Hu A; Hillel AD
    Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
    Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
    Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients.
    Patel AB; Bansberg SF; Adler CH; Lott DG; Crujido L
    Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):859-63. PubMed ID: 26024910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voice tuning with new instruments for type II thyroplasty in the treatment of adductor spasmodic dysphonia.
    Sanuki T; Yumoto E; Toya Y; Kumai Y
    Auris Nasus Larynx; 2016 Oct; 43(5):537-40. PubMed ID: 26811303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term voice handicap index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia.
    Sanuki T; Yumoto E; Kodama N; Minoda R; Kumai Y
    Auris Nasus Larynx; 2014 Jun; 41(3):285-9. PubMed ID: 24369905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of unilateral thalamic deep brain stimulation on the vocal dysfunction in a patient with spasmodic dysphonia: interrogating cerebellar and pallidal neural circuits.
    Poologaindran A; Ivanishvili Z; Morrison MD; Rammage LA; Sandhu MK; Polyhronopoulos NE; Honey CR
    J Neurosurg; 2018 Feb; 128(2):575-582. PubMed ID: 28304188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response.
    Tanner K; Roy N; Merrill RM; Sauder C; Houtz DR; Smith ME
    Ann Otol Rhinol Laryngol; 2011 Jul; 120(7):465-73. PubMed ID: 21859056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
    Lerner MZ; Lerner BA; Patel AA; Blitzer A
    Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type II thyroplasty changes cortical activation in patients with spasmodic dysphonia.
    Tateya I; Omori K; Kojima H; Naito Y; Hirano S; Yamashita M; Ito J
    Auris Nasus Larynx; 2015 Apr; 42(2):139-44. PubMed ID: 25199736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.